Factors associated with the publication of scholarly articles by pharmacists.

PURPOSE: Factors associated with the publication of scholarly articles by pharmacists were evaluated. METHODS: A Web-based survey was distributed to all pharmacists who published at least one scholarly article in selected pharmacy and medical journals in 2008. All scholarly works published in the American Journal of Health-System Pharmacy, Annals of Pharmacotherapy, and Pharmacotherapy during the study period were categorized by study design using a predetermined algorithm. A secondary group of pharmacists who published in at least 1 of 10 selected medical journals during the study period was also evaluated to identify any differences between those who published in pharmacy versus medical journals. RESULTS: The final number of usable responses was 254, for an adjusted response rate of 72.9%. Factors identified as the most helpful for facilitating publication efforts included time allotment, mentorship, and collaborative efforts. "Lack of time" was reported as the most important barrier to publication. The majority of respondents (73%, n = 182) published their first article during a training program (academic program, residency, or fellowship). Of the 468 scholarly works published in the selected pharmacy journals during the study period, review articles were most common (38.7%, n = 177). CONCLUSION: The most influential factors on the publication efforts by pharmacists were time allotment, collaboration between pharmacy colleagues and within multidisciplinary teams, and training in research methods and scientific writing. Introduction to the publication process during training programs appeared to influence future propensity toward scholarly participation. Review and descriptive articles were the most frequently published types of articles in the pharmacy literature.

Evaluation of contraindicated drug-drug interaction alerts in a hospital setting.

BACKGROUND: Risks associated with contraindicated drug-drug interaction alerts (CDDIAs) should always outweigh benefits. Misclassified CDDIAs should be eliminated. OBJECTIVE: To review CDDIAs and determine if they are contraindicated according to Food and Drug Administration-approved product labeling and if there are circumstances in which contraindicated interactions are acceptable. METHODS: A cross-sectional observational and quality improvement study was conducted over two 1-year periods. The 20 most common CDDIAs from May 2007 to May 2008 and all CDDIAs from April 2008 to April 2009 were collected at a large teaching hospital. Horizon Meds Manager used First DataBank as the knowledge base for decision support. Interactions were deemed truly contraindicated if listed in the contraindications section of the labeling of at least one of the interacting drugs. Alerts were grouped by drug and pharmacologic class to evaluate the evidence supporting the relevance of these interactions. An expert panel determined when an alert was misclassified. A medical advisory committee determined whether a contraindicated drug-drug combination was acceptable. RESULTS: Twelve (60%) of the most common 20 contraindicated interaction pairs from 2007 to 2008 were inappropriately classified. Half of the alerts were not truly contraindicated. The 8 truly contraindicated drug-drug pairs were ketorolac and other nonsteroidal antiinflammatory drugs or oral solid potassium products and anticholinergics. Half of these interactions were subsequently deemed acceptable under specific circumstances. Similar results were found in the second year, with only 55.1% of all CDDIAs being truly contraindicated despite eliminating some of the alerts that were misclassified in the first year. Nearly three fourths of legitimate CDDIAs were deemed acceptable under specific circumstances. CONCLUSIONS: Most contraindicated drug-drug interaction alerts from a commercial knowledge base were inappropriately categorized and could be downgraded. Some contraindicated drug combinations are permissible under specific circumstances. Alerts suggesting that certain drugs should never be used together, but their use together is sometimes acceptable, contribute to alert fatigue.